COMPASS Pathways

United Kingdom
Altrincham, England, United Kingdom, WA14 2DT

Company profile

COMPASS Pathways company profile

Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression. The company is involved in researching and developing psilocybin therapy, a psychedelic compound found in certain mushrooms, as a potential treatment for depression. Compass Pathways conducts clinical trials and research to assess the safety and efficacy of psilocybin-assisted therapy in patients who have not responded to conventional depression treatments. The company's goal is to bring evidence-based innovation to mental health care and address the significant unmet need for effective and accessible treatments for depression.

Business identity

Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$1M-$10M
Founded
2016-06-13

Headquarters

Postal code
WA14 2DT
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
7
Total equity funding
$391.2M
Last funding
Post IPO Equity / $150M / 2025-01-10
Last equity funding
Post IPO Equity / $150M
Investors
24
Lead investors
4
Founders
3
Articles
223
Exited on
2020-09-18

Founders and investors

Founders

Ekaterina MalievskaiaGeorge GoldsmithLars Wilde

Lead investors

Aisling CapitalHercules CapitalMcQuade Center for Strategic Research and DevelopmentTCG Crossover

Investors

Founders FundPerceptive AdvisorsRA Capital ManagementTCG CrossoverVivo Capital